Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decision

Heart. 2015 Jun;101(11):832-3. doi: 10.1136/heartjnl-2014-307356. Epub 2015 Apr 3.

Authors

Denis Angoulvant¹, Theodora Bejan Angoulvant², Laurent Fauchier¹

Affiliations

¹ Service de Cardiologie, Pôle Cœur Thorax Vasculaire, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, Université François Rabelais, Tours, France.
² Service de Pharmacologie clinique, Centre Hospitalier Universitaire Bretonneau et Faculté de Médecine, Université François Rabelais, Tours, France.

PMID: 25841162
DOI: 10.1136/heartjnl-2014-307356

No abstract available

Publication types

Editorial
Comment

MeSH terms

Female
Humans
Male
Myocardial Infarction / drug therapy*
Piperazines / adverse effects*
Platelet Aggregation Inhibitors / adverse effects*
Purinergic P2Y Receptor Antagonists / adverse effects*
Thiophenes / adverse effects*
Ticlopidine / analogs & derivatives*

Substances

Piperazines
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Thiophenes
Ticlopidine